Advertisement
Advertisement
CSTL
Castle Biosciences, Inc. Common Stock
32.52
USDSponsored
-1.68
-4.91%
Nov 06, 15:59 UTC -5
Closed
After-Market
32.98
+0.46
+1.43%
Castle Biosciences, Inc. Common Stock (CSTL) Earnings
CSTL Earnings Reports
Positive Surprise Ratio
CSTL beat 24 of 30 last estimates.
80%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$96.28M
/-$0.38
Implied change from Q3 26 (Revenue/ EPS)
-6.43%
/+192.31%
Implied change from Q4 25 (Revenue/ EPS)
+10.65%
/+375.00%
Castle Biosciences, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, CSTL reported earnings of -0.13 USD per share (EPS) for Q3 26, beating the estimate of -0.37 USD, resulting in a 65.32% surprise. Revenue reached 102.89 million, compared to an expected 94.37 million, with a 9.02% difference. The market reacted with a -4.91% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.38 USD, with revenue projected to reach 96.28 million USD, implying an increase of 192.31% EPS, and decrease of -6.43% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
FAQ
What were Castle Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Castle Biosciences, Inc. Common Stock reported EPS of -$0.13, beating estimates by 65.32%, and revenue of $102.89M, 9.02% above expectations.
How did the market react to Castle Biosciences, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -4.91%, changed from $34.20 before the earnings release to $32.52 the day after.
When is Castle Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Castle Biosciences, Inc. Common Stock's next earnings report?
Based on --
analysts, Castle Biosciences, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of $96.28M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.